Caxton Associates LP Purchases 700 Shares of Quest Diagnostics Inc (DGX)
Caxton Associates LP boosted its position in Quest Diagnostics Inc (NYSE:DGX) by 11.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,700 shares of the medical research company’s stock after purchasing an additional 700 shares during the quarter. Caxton Associates LP’s holdings in Quest Diagnostics were worth $627,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DGX. WFG Advisors LP boosted its stake in Quest Diagnostics by 45.3% in the 2nd quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock valued at $107,000 after purchasing an additional 301 shares during the period. Sun Life Financial INC boosted its stake in Quest Diagnostics by 14,142.9% in the 2nd quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock valued at $111,000 after purchasing an additional 990 shares during the period. Parallel Advisors LLC boosted its stake in Quest Diagnostics by 0.9% in the 2nd quarter. Parallel Advisors LLC now owns 1,291 shares of the medical research company’s stock valued at $140,000 after purchasing an additional 12 shares during the period. Acrospire Investment Management LLC boosted its stake in Quest Diagnostics by 300.0% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,600 shares of the medical research company’s stock valued at $178,000 after purchasing an additional 1,200 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in Quest Diagnostics in the 2nd quarter valued at $180,000. Institutional investors and hedge funds own 89.20% of the company’s stock.
Quest Diagnostics Inc (NYSE:DGX) opened at $97.09 on Monday. The firm has a market capitalization of $13,230.00, a price-to-earnings ratio of 17.40, a price-to-earnings-growth ratio of 2.02 and a beta of 0.60. The company has a quick ratio of 1.37, a current ratio of 1.47 and a debt-to-equity ratio of 0.78. Quest Diagnostics Inc has a fifty-two week low of $89.46 and a fifty-two week high of $112.96.
Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, October 19th. The medical research company reported $1.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.35 by $0.04. Quest Diagnostics had a return on equity of 15.53% and a net margin of 8.82%. The firm had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.92 billion. During the same period in the previous year, the firm earned $1.37 EPS. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. equities research analysts anticipate that Quest Diagnostics Inc will post 5.65 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Stockholders of record on Tuesday, January 9th will be issued a dividend of $0.45 per share. The ex-dividend date of this dividend is Monday, January 8th. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.85%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 37.50%.
In other news, Chairman Stephen H. Rusckowski sold 59,235 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $108.16, for a total transaction of $6,406,857.60. Following the completion of the transaction, the chairman now owns 220,049 shares of the company’s stock, valued at approximately $23,800,499.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.75% of the stock is currently owned by insiders.
Several research firms recently issued reports on DGX. ValuEngine upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. Canaccord Genuity restated a “buy” rating and issued a $118.00 price target on shares of Quest Diagnostics in a research note on Wednesday, September 13th. BidaskClub upgraded Quest Diagnostics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 15th. Raymond James Financial reaffirmed a “market perform” rating on shares of Quest Diagnostics in a report on Monday, September 25th. Finally, KeyCorp reaffirmed a “hold” rating on shares of Quest Diagnostics in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and seven have issued a buy rating to the company. Quest Diagnostics has a consensus rating of “Hold” and a consensus price target of $106.28.
WARNING: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/caxton-associates-lp-purchases-700-shares-of-quest-diagnostics-inc-dgx/1757352.html.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.